* Some of Neoprobe Corp.'s second-quarter results in theAug. 15, 1995 issue of BioWorld Today were incorrectlyreported. For the quarter ending June 30, 1995, Neoprobehad revenues of $278,000, a 31 percent increase from thesecond quarter of 1994. Its net loss was $2.56 million, or18 cents per share, vs. $2.06 million, or 25 cents, in 1994.Research and development spending increased 26percent, to $1.7 million. The company had $11.9 millionin cash and equivalents and 14 million sharesoutstanding.

* An article in the Aug. 11, 1995 issue of BioWorldToday incorrectly stated that a column criticizing theBiotechnology Industry Organization's stance on FDAreform appeared in the San Jose Mercury News. Theeditorial column focused on the Clinton administration.

(c) 1997 American Health Consultants. All rights reserved.